Impact of Smoking Status on Growth Differentiation Factor 15 and Mortality in Patients With Suspected or Known Coronary Artery Disease: The ANOX Study

Autor: Takashi Takenaka, Toshihiro Nakamura, Kazuhiko Kotani, Toru Kato, Akihiro Yasoda, Moritake Iguchi, Masahiro Suzuki, Hiromichi Wada, Nobutoyo Masunaga, Tsuyoshi Shinozaki, Masaharu Akao, Akira Shimatsu, Daisuke Takagi, Junichi Funada, Mitsuru Abe, Mitsuru Ishii, Hajime Yamakage, Masatoshi Shimizu, Kazuteru Fujimoto, Hiromi Matsubara, Kazuya Yonezawa, Takashi Unoki, Yoichi Ajiro, Toru Kusakabe, Noriko Satoh-Asahara, Morihiro Matsuda, Kyohma Wada, Koji Hasegawa, Satoru Sakagami, Miyaka Wada, Yukiko Morita
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Oncology
Adult
Male
medicine.medical_specialty
Growth Differentiation Factor 15
Coronary Artery Disease
030204 cardiovascular system & hematology
smoking
Coronary artery disease
Cohort Studies
03 medical and health sciences
Young Adult
0302 clinical medicine
Risk Factors
Internal medicine
Clinical Studies
medicine
Coronary Heart Disease
Humans
In patient
030212 general & internal medicine
Prospective cohort study
Original Research
Aged
all‐cause death
Aged
80 and over
prospective cohort study
business.industry
Middle Aged
medicine.disease
Prognosis
Survival Rate
Growth Factors/Cytokines
embryonic structures
Biomarker (medicine)
biomarker
Smoking status
Female
Known Coronary Artery Disease
GDF15
Mortality/Survival
Cardiology and Cardiovascular Medicine
business
All cause mortality
Biomarkers
Zdroj: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
ISSN: 2047-9980
Popis: Background Whether circulating growth differentiation factor 15 (GDF‐15) levels differ according to smoking status and whether smoking modifies the relationship between GDF‐15 and mortality in patients with coronary artery disease are unclear. Methods and Results Using data from a multicenter, prospective cohort of 2418 patients with suspected or known coronary artery disease, we assessed the association between smoking status and GDF‐15 and the impact of smoking status on the association between GDF‐15 and all‐cause death. GDF‐15 was measured in 955 never smokers, 1035 former smokers, and 428 current smokers enrolled in the ANOX Study (Development of Novel Biomarkers Related to Angiogenesis or Oxidative Stress to Predict Cardiovascular Events). Patients were followed up during 3 years. The age of the patients ranged from 19 to 94 years; 67.2% were men. Never smokers exhibited significantly lower levels of GDF‐15 compared with former smokers and current smokers. Stepwise multiple linear regression analysis revealed that the log‐transformed GDF‐15 level was independently associated with both current smoking and former smoking. In the entire patient cohort, the GDF‐15 level was significantly associated with all‐cause death after adjusting for potential clinical confounders. This association was still significant in never smokers, former smokers, and current smokers. However, GDF‐15 provided incremental prognostic information to the model with potential clinical confounders and the established cardiovascular biomarkers in never smokers, but not in current smokers or in former smokers. Conclusions Not only current, but also former smoking was independently associated with higher levels of GDF‐15. The prognostic value of GDF‐15 on mortality was most pronounced in never smokers among patients with suspected or known coronary artery disease.
Databáze: OpenAIRE
Externí odkaz: